Observational studyCancer medicine2019
Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
Observational study in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Article
- Emerging Artificial Intelligence Models for Estimating Breslow Thickness from Dermoscopic Images.Biomedicines · 2026Review
- Bridging gaps throughout a patient's journey with melanoma: a systematic review.Melanoma management · 2025Review
- Nevus-Associated and De Novo Melanoma: A Cross-Sectional Study on Prognostic Differences.Cancers · 2025Article
- Treatment Patterns and Outcomes of Stage III Melanoma Patients with Positive Sentinel Lymph Node Biopsy: A Real-Life Experience.Journal of clinical medicine · 2024Article
- Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort.World journal of surgical oncology · 2024Article
- Intranodal Injection of Immune Activator Demonstrates Antitumor Efficacy in an Adjuvant Approach.Vaccines · 2024Article
- Invasive Cutaneous Melanoma: Evaluating the Prognostic Significance of Some Parameters Associated with Lymph Node Metastases.Medicina (Kaunas, Lithuania) · 2023Article
- The Characteristics of Sentinel Lymph Node Biopsy in Cutaneous Melanoma and the Particularities for Elderly Patients-Experience of a Single Clinic.Diagnostics (Basel, Switzerland) · 2023Article
- Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma.International journal of molecular sciences · 2022Review
- Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View.Medicina (Kaunas, Lithuania) · 2022Review
- Sentinel lymph node biopsy in melanoma: beyond histologic factors.Clinical & experimental metastasis · 2022Review
- Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma: A Multicenter Propensity Score Matching Study.Journal of clinical medicine · 2021Article
- Risk factors for positive sentinel lymph node, lymphatic or hematogenous dissemination over time in patients with cutaneous melanoma.Experimental and therapeutic medicine · 2021Article
- Dermoscopic Features as Predictors ofDermatology practical & conceptual · 2021Review
- Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.Current treatment options in oncology · 2021Review
- Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.JCO precision oncology · 2021Article
- RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study.Frontiers in oncology · 2021Article
- Protocol for the Histologic Diagnosis of Cutaneous Melanoma: Consensus Statement of the Spanish Society of Pathology and the Spanish Academy of Dermatology and Venereology (AEDV) for the National Cutaneous Melanoma Registry.Actas dermo-sifiliograficas · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 13 institutions in 3 countries.
Funding
Abstract
Mitotic rate is no longer considered a staging criterion for thin melanoma in the 8th edition of the American Joint Committee on Cancer Staging Manual. The aim of this observational study was to identify prognostic factors for thin melanoma and predictors and prognostic significance of sentinel lymph node (SLN) involvement in a large multicenter cohort of patients with melanoma from nine tertiary care hospitals. A total of 4249 consecutive patients with thin melanoma diagnosed from January 1, 1998 to December 31, 2016 were included. The main outcomes were disease-free interval and melanoma-specific survival for the overall population and predictors of SLN metastasis (n = 1083). Associations between survival and SLN status and different clinical and pathologic variables (sex, age, tumor location, mitosis, ulceration, regression, lymphovascular invasion, histologic subtype, Clark level, and Breslow thickness) were analyzed by Cox proportional hazards regression and logistic regression. SLN status was the most important prognostic factor for melanoma-specific survival (hazard ratio, 13.8; 95% CI, 6.1-31.2; P < 0.001), followed by sex, ulceration, and Clark level for patients who underwent SLNB. A mitotic rate of >2 mitoses/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.